Millennium reports 4.2% stake in Phathom Pharma
Phathom Pharmaceuticals, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Phathom Pharmaceuticals, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filers report beneficial ownership of 3,375,834 shares of Phathom common stock, representing 4.2% of the class. They report 0 shares with sole voting or dispositive power and 3,375,834 shares with shared voting and shared dispositive power. The filing indicates that the group now holds 5 percent or less of the outstanding common stock. A joint filing agreement dated July 17, 2026 governs this combined reporting.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G/A regulatory
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in PHAT does Millennium Management report in this Schedule 13G/A?
Who are the reporting persons in the Phathom Pharmaceuticals (PHAT) Schedule 13G/A filing?
What percentage of Phathom Pharmaceuticals (PHAT) stock is reported as beneficially owned?
Does the Millennium group report owning more than 5% of Phathom Pharmaceuticals (PHAT)?
What agreement governs the joint Schedule 13G/A filing for Phathom Pharmaceuticals (PHAT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.